Springer SA, et al. - The researchers assessed if extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use disorder (OUD) transitioning to the community. They performed a 4-site, prospective randomized double-blind, placebo-controlled trial among prison and jail inmates with HIV and OUD transitioning to the community from September 2010 through March 2016 and identified that XR-NTX improves or maintains VS after release to the community for these incarcerated individuals.